Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 5,354 matching trials from the live ClinicalTrials.gov search.

Filters: Milwaukee, Wisconsin Clear all

Conditions: Sarcoma
Interventions: topotecan hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity, Radiation Toxicity
Interventions: Rituximab, Cytarabine, Methotrexate, Procarbazine, Vincristine, low-dose whole-brain radiation therapy; Biological · Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 34 more

Conditions: Physical Function
Interventions: RT; Behavioral
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 65 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Colorectal Cancer
Interventions: FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 121
States / cities: Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 100 more

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission
Interventions: Compliance Monitoring, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Questionnaire Administration, Study of Socioeconomic and Demographic Variables; Behavioral · Other · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2020
U.S. locations: 124
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 105 more

Conditions: Aspiration, Gastroesophageal Reflux
Interventions: Tracheal Lavage; Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 1 Year to 18 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Keratitis, Herpetic, Ocular Herpes Simplex, Herpes Simplex
Interventions: Stress, Acyclovir; Behavioral · Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1992
U.S. locations: 8
States / cities: San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Stress Disorders, Post-Traumatic
Interventions: Yoga Intervention; Other
Lead sponsor: Marquette University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Chronic Lung Disease
Interventions: gene variations; Genetic
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 29
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 24 more

Conditions: Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions: ornithine phenylacetate, placebo intravenous infusion; Drug
Lead sponsor: Ocera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin; Drug · Biological
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 50 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 71
States / cities: Birmingham, Alabama • Irvine, California • Orange, California + 60 more

Conditions: Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Interventions: Sigvotatug Vedotin, Pembrolizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 84
States / cities: Fullerton, California • Golden, Colorado • Grand Junction, Colorado + 56 more

Conditions: Carcinoma, Renal Cell
Interventions: Bay 59-8862; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 13
States / cities: La Jolla, California • Muncie, Indiana • New Orleans, Louisiana + 9 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, Sotorasib; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 180
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more

Conditions: Delayed Graft Function
Interventions: ANG-3777, Placebo; Drug · Other
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 30
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more

Conditions: Traumatic Injury, PTSD, Posttraumatic Stress Disorder
Interventions: Treatment as Usual, Brief Prolonged Exposure Therapy; Behavioral
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Dallas, Texas • Temple, Texas • Milwaukee, Wisconsin

Conditions: Psoriasis
Interventions: Apremilast, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 32
States / cities: Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 26 more

Conditions: Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, Pegylated Liposomal Doxorubicin Hydrochloride; Other · Biological · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: Birmingham, Alabama • Orange, California • St Louis, Missouri + 4 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 22
States / cities: Duarte, California • Orange, California • Palo Alto, California + 19 more

Conditions: Lower Respiratory Tract Infection
Interventions: MeMed BV test; Diagnostic Test
Lead sponsor: MeMed Diagnostics Ltd.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 1,316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Jacksonville, Florida • Kansas City, Kansas • Brooklyn, New York + 5 more

Conditions: Steroid-Refractory Acute Graft Versus Host Disease
Interventions: T-Guard; Drug
Lead sponsor: Xenikos; Industry
Eligibility: 12 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 24
States / cities: Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 20 more

Conditions: Pancreatic Cancer
Interventions: ABI-007; Drug
Lead sponsor: Celgene; Industry
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 16
States / cities: Scottsdale, Arizona • Long Beach, California • Aurora, Colorado + 12 more

Conditions: Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions: Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rituximab, Temsirolimus; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 11
States / cities: Denver, Colorado • Atlanta, Georgia • Rochester, Minnesota + 7 more

Search by objective public record fields.

Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Resistance Training to Improve Physical Function in the Elderly

Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Pepsin As A Biomarker For Aspiration

Herpetic Eye Disease Study (HEDS) II

Feasibility of a Yoga Program for Veterans With PTSD

Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants

A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney

Trauma BPE Prolonged Exposure Therapy for Injured Individuals Admitted to a Level I Trauma Center

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma